This non-interventional, observational, open-label multi-center follow-up study of patients from the U-Act-Early trial (ML22497) will evaluate the long-term efficacy and safety of starting tight control treatment with RoActemra/Actemra (tocilizumab) and/or methotrexate in patients early in the disease followed by treatment according to standard of care in routine clinical practice in a three year follow-up, independently of what treatment the patient will be receiving.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01918267?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
